1. Home
  2. SPCB vs XLO Comparison

SPCB vs XLO Comparison

Compare SPCB & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SuperCom Ltd. (Israel)

SPCB

SuperCom Ltd. (Israel)

HOLD

Current Price

$9.25

Market Cap

38.7M

Sector

Technology

ML Signal

HOLD

XLO

Xilio Therapeutics Inc.

HOLD

Current Price

$0.76

Market Cap

41.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SPCB
XLO
Founded
1988
2016
Country
Israel
United States
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
38.7M
41.8M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
SPCB
XLO
Price
$9.25
$0.76
Analyst Decision
Strong Buy
Buy
Analyst Count
1
1
Target Price
$18.00
$2.00
AVG Volume (30 Days)
104.4K
798.0K
Earning Date
11-13-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.84
N/A
Revenue
$26,739,000.00
$31,804,000.00
Revenue This Year
N/A
$519.70
Revenue Next Year
$29.31
$44.57
P/E Ratio
$11.03
N/A
Revenue Growth
N/A
588.40
52 Week Low
$3.08
$0.62
52 Week High
$18.95
$1.70

Technical Indicators

Market Signals
Indicator
SPCB
XLO
Relative Strength Index (RSI) 45.62 46.74
Support Level $7.98 $0.73
Resistance Level $9.49 $0.76
Average True Range (ATR) 0.80 0.05
MACD 0.01 -0.00
Stochastic Oscillator 46.95 54.21

Price Performance

Historical Comparison
SPCB
XLO

About SPCB SuperCom Ltd. (Israel)

SuperCom Ltd is an Israel-based provider of traditional and digital identity solutions, providing safety, identification, tracking, and security products to governments and organizations. The company comprises three main Strategic Business Units: e-Gov; IoT, which is the key revenue driver; and Cyber Security. The Company's IoT products and solutions reliably identify, track and monitor people or objects in real time, enabling the customers to detect unauthorized movement of people, vehicles and other monitored objects. The geographical segments of the company include Africa, European countries, South America, the United States, Israel, and APAC.

About XLO Xilio Therapeutics Inc.

Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies and immune cell engagers.

Share on Social Networks: